Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | LSS | P48449 | 9/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21176624 | 0.81 | SNCA (0.41) | ESR1 | |
| SCHEMBL21176622 | 0.80 | ESR1 (0.52) | ESR1MEN1KMT2A | |
| SCHEMBL21176524 | 0.75 | ESR1 (0.76) | ESR1ESR2 | |
| SCHEMBL4493624 | 0.71 | NQO1 (0.50) | MAPTALDH1A1KDM4E | |
| SCHEMBL15659875 | 0.68 | ESR1 (0.70) | ESR1MAPTALDH1A1KDM4E | |
| SCHEMBL5040359 | 0.67 | LSS (0.44) | LSS | |
| SCHEMBL21176572 | 0.66 | TUBB4A (0.42) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5038195 | 0.66 | LSS (0.41) | LSS | |
| SCHEMBL14782318 | 0.65 | ALDH1A1 (0.55) | MAPTALDH1A1HSD17B10KDM4EMEN1 | |
| SCHEMBL6864771 | 0.65 | MAPT (0.52) | MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200360543-A1 | RADIOTRACERS FOR IMAGING ER-POSITIVE BREAST CANCER | UNIV ILLINOIS (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200360543-A1 | RADIOTRACERS FOR IMAGING ER-POSITIVE BREAST CANCER | UNIV ILLINOIS (US) | 2020-11-19 | — | — | US | disclosed |
| US-20190224346-A1 | RADIOTRACERS FOR IMAGING ER-POSITIVE BREAST CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190224346-A1 | RADIOTRACERS FOR IMAGING ER-POSITIVE BREAST CANCER | ESRRG, ESR1, ESR2 | ESR1 2/4885ESR2 3/4885LSS 3334/4885 |
| US-20200360543-A1 | RADIOTRACERS FOR IMAGING ER-POSITIVE BREAST CANCER | ESRRG, ESR1, ESR2 | ESR1 2/4885ESR2 3/4885LSS 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.